Looking Forward to the Future of Heparin: New Sources, Developments and Applications
This book is a printed edition of the Special Issue Looking Forward to the Future of Heparin: New Sources, Developments and Applications that was published in Molecules
Saved in:
| : | |
|---|---|
| Year of Publication: | 2018 |
| Language: | English |
| Physical Description: | 1 electronic resource (282 p.) |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| LEADER | 04094nam-a2201345z--4500 | ||
|---|---|---|---|
| 001 | 993544005904498 | ||
| 005 | 20231214132955.0 | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 202102s2018 xx |||||o ||| 0|eng d | ||
| 020 | |a 3-03842-950-3 | ||
| 035 | |a (CKB)4920000000095222 | ||
| 035 | |a (oapen)https://directory.doabooks.org/handle/20.500.12854/51985 | ||
| 035 | |a (EXLCZ)994920000000095222 | ||
| 041 | 0 | |a eng | |
| 100 | 1 | |a Fareed, Jawed |4 auth | |
| 245 | 1 | 0 | |a Looking Forward to the Future of Heparin: New Sources, Developments and Applications |
| 246 | |a Looking Forward to the Future of Heparin | ||
| 260 | |b MDPI - Multidisciplinary Digital Publishing Institute |c 2018 | ||
| 300 | |a 1 electronic resource (282 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 520 | |a This book is a printed edition of the Special Issue Looking Forward to the Future of Heparin: New Sources, Developments and Applications that was published in Molecules | ||
| 546 | |a English | ||
| 653 | |a alginate | ||
| 653 | |a edema | ||
| 653 | |a Heparin Red | ||
| 653 | |a solid lipid nanoparticles | ||
| 653 | |a Fe3O4·DA-BSA/HA | ||
| 653 | |a dermatan sulfate | ||
| 653 | |a sulfated alginate | ||
| 653 | |a porcine heparin | ||
| 653 | |a theranostics | ||
| 653 | |a low-molecular-weight heparin | ||
| 653 | |a Arixtra® | ||
| 653 | |a biomaterials | ||
| 653 | |a hepcidin | ||
| 653 | |a ovarian cancer | ||
| 653 | |a iron oxide nanoparticles | ||
| 653 | |a heparin-induced thrombocytopenia | ||
| 653 | |a bone morphogenetic protein (BMP) | ||
| 653 | |a hyaluronic acid (HA) | ||
| 653 | |a crude heparin | ||
| 653 | |a platelets | ||
| 653 | |a resistance | ||
| 653 | |a sclerostin | ||
| 653 | |a LMWH | ||
| 653 | |a gremlin | ||
| 653 | |a low molecular weight heparin (LMWH) | ||
| 653 | |a low molecular weight glycosaminoglycans | ||
| 653 | |a human plasma | ||
| 653 | |a single crystal X-ray structure | ||
| 653 | |a iron homeostasis | ||
| 653 | |a noggin | ||
| 653 | |a super paramagnetic iron oxide nanoparticles (SPION) | ||
| 653 | |a manufacturing methods | ||
| 653 | |a paclitaxel (PTX) | ||
| 653 | |a brain injury | ||
| 653 | |a bovine heparin | ||
| 653 | |a inflammation | ||
| 653 | |a qNMR | ||
| 653 | |a antithrombin | ||
| 653 | |a reference standard | ||
| 653 | |a quantitative NMR | ||
| 653 | |a enoxaparin | ||
| 653 | |a danaparoid sodium | ||
| 653 | |a NMR | ||
| 653 | |a GDNF | ||
| 653 | |a orthogonal multi-analytical methods | ||
| 653 | |a ternary complex | ||
| 653 | |a heparan sulphate | ||
| 653 | |a serglycin | ||
| 653 | |a bovine serum albumin (BSA) | ||
| 653 | |a HSQC | ||
| 653 | |a recombinant expression | ||
| 653 | |a heparin | ||
| 653 | |a heparin oligosaccharides | ||
| 653 | |a functional assay | ||
| 653 | |a BMP antagonists | ||
| 653 | |a intestinal lymphatic absorption | ||
| 653 | |a size exclusion chromatography | ||
| 653 | |a heparin coating | ||
| 653 | |a diagnosis | ||
| 653 | |a bioreactor | ||
| 653 | |a anemia | ||
| 653 | |a proteoglycan | ||
| 653 | |a heparin process | ||
| 653 | |a PCA | ||
| 653 | |a chemometric | ||
| 653 | |a fluorescent probe | ||
| 653 | |a pharmacopeia | ||
| 653 | |a affinity chromatography | ||
| 653 | |a component quantitative analysis | ||
| 653 | |a Fondaparinux sodium | ||
| 653 | |a perylene diimide dyes | ||
| 653 | |a thrombin inhibition | ||
| 653 | |a extended physicochemical characterization | ||
| 653 | |a cisplatin | ||
| 653 | |a glycosaminoglycans | ||
| 653 | |a TGF-? | ||
| 653 | |a chondroitin sulfate | ||
| 653 | |a dalteparin | ||
| 653 | |a sequence and compositional investigations | ||
| 653 | |a molecular weight | ||
| 653 | |a magnetic resonance imaging (MRI) | ||
| 653 | |a industrial | ||
| 653 | |a LC-MS | ||
| 653 | |a iduronic acid conformation | ||
| 653 | |a heparan sulfate | ||
| 653 | |a growth and differentiation factor (GDF) | ||
| 653 | |a assay | ||
| 653 | |a subarachnoid hemorrhage | ||
| 776 | |z 3-03842-949-X | ||
| 700 | 1 | |a Torri, Giangiacomo |4 auth | |
| 906 | |a BOOK | ||
| ADM | |b 2024-03-07 03:45:29 Europe/Vienna |f system |c marc21 |a 2019-11-10 04:18:40 Europe/Vienna |g false | ||
| AVE | |i DOAB Directory of Open Access Books |P DOAB Directory of Open Access Books |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5337474310004498&Force_direct=true |Z 5337474310004498 |b Available |8 5337474310004498 | ||